MedTrace Logo

Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan

NCT00688870 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2022-10-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly with routine vaccines in Taiwan.

Conditions

  • Vaccines
  • Pneumococcal Conjugate Vaccine

Interventions

BIOLOGICAL

13-valent pneumococcal conjugate vaccine (13vPnC)

13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.

BIOLOGICAL

7-valent pneumococcal conjugate vaccine (7vPnC)

7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
42 Days
Max Age
98 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-05
Primary Completion
2010-01-13
Completion
2010-01-13

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688870 on ClinicalTrials.gov